Engitix Announces Appointment of Sonia Quaratino, M.D., Ph.D., as Independent Non-executive Director
May 09, 2023 04:00 ET
|
Engitix Therapeutics
LONDON, May 09, 2023 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human...
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
April 03, 2023 07:00 ET
|
FibroGen, Inc.
- 372 IPF Patients Enrolled -- Topline Data Anticipated Mid-2024 - SAN FRANCISCO, April 03, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the completion of patient...
aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis
January 19, 2023 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment
December 15, 2022 08:00 ET
|
aTyr Pharma, Inc.
LTBP1 is key regulator of TGF-β, a major driver of fibrosis. Latest target identified from company’s platform in collaboration with Dualsystems Biotech AG. SAN DIEGO, Dec. 15, 2022 (GLOBE...
Inventiva organise un webcast avec des leaders d’opinion à l’occasion de l’EASL International Liver Congress™ 2022
June 16, 2022 16:00 ET
|
INVENTIVA
Point sur l’étude clinique de Phase III NATiV3 d'Inventiva évaluant lanifibranor chez les patients atteints de NASH et de fibrose (stade F2/F3) non cirrhotique par le Prof. Sven FrancquePoint sur le...
Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022
June 16, 2022 16:00 ET
|
INVENTIVA
Update on Inventiva’s NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH and fibrosis (stage F2/F3) non-cirrhotic by Prof. Sven FrancqueUpdate on the current NASH landscape...
Inventiva annonce la présentation de trois abstracts scientifiques lors de l’EASL International Liver Congress™ 2022
June 09, 2022 16:00 ET
|
INVENTIVA
Trois présentations par poster démontrant : les effets bénéfiques de lanifibranor sur les marqueurs de la santé cardiométabolique chez les patients atteints de NASH avec fibrose non cirrhotique,...
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022
June 09, 2022 16:00 ET
|
INVENTIVA
Three poster presentations showing the beneficial effects of lanifibranor on markers of cardiometabolic health in patients with non-cirrhotic NASH fibrosis independent of weight gain observed.the...
Inventiva obtient un crédit d’un montant de 50 millions d’euros de la part de la Banque Européenne d’Investissement
May 16, 2022 02:00 ET
|
INVENTIVA
Ce financement doit permettre de soutenir la croissance et le développement du portefeuille de R&D d'InventivaLe crédit est composé de deux tranches de 25 millions d'euros chacune Cet accord...
Inventiva secures a €50 million credit facility from the European Investment Bank
May 16, 2022 02:00 ET
|
INVENTIVA
This credit facility is intended to support the progress and expansion of Inventiva’s pipelineThe credit facility consists of two tranches of €25 million eachCredit agreement is part of the European...